Efficacy and Safety Study of Ingavirin® to Treat Influenza and Other Acute Respiratory Viral Infections in Patients 3-6 y.o.

PHASE3CompletedINTERVENTIONAL
Enrollment

190

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

May 31, 2016

Study Completion Date

May 31, 2016

Conditions
Common ColdInfluenza
Interventions
DRUG

Imidazolyl ethanamide pentandioic acid

DRUG

placebo

Trial Locations (13)

Unknown

"GBOU VPO Kazan State Medical University of Ministry of Health of Russian Federation", Kazan'

"GBOU VPO Krasnoyarsk State Medical University n.a.n V.F. Voyno-Yasenetskogo of Ministry of Health of Russian Federation", Krasnoyarsk

"FGBU Scientific center of children health of the Ministry of Health of Russian Federation", Moscow

I.M. Sechenov First Moscow State Medical University, Moscow

"Moscow Budgetary Public Health Facility Infectious clinical hospital #1 of Moscow City Health Department", Moscow

"GBOU VPO Novosibirsk State Medical University of Ministry of Health of Russian Federation", Novosibirsk

Children's city outpatients clinic № 5, Perm

Children's city outpatients clinic № 4, Rostov-on-Don

"GBOU VPO Rostov State Medical University of Ministry of Health of Russian Federation", Rostov-on-Don

"FGBU Scientific Research Institute of Children's Infections, Federal Biomedical Agency", Saint Petersburg

"FGBOU VPO Mordov State University n.a. N.P. Ogarev", Saransk

"GBOU VPO Siberia State Medcial University of Ministry of Health of Russian Federation", Tomsk

"GBOU VPO Yaroslavl State Medical University of Ministry of Health of Russian Federation", Yaroslavl

All Listed Sponsors
collaborator

Atlant Clinical Ltd.

OTHER

lead

Valenta Pharm JSC

INDUSTRY

NCT02644018 - Efficacy and Safety Study of Ingavirin® to Treat Influenza and Other Acute Respiratory Viral Infections in Patients 3-6 y.o. | Biotech Hunter | Biotech Hunter